These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33224690)

  • 21. An open-label trial of risperidone augmentation for refractory anxiety disorders.
    Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
    J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generalised anxiety disorder in elderly patients : epidemiology, diagnosis and treatment options.
    Flint AJ
    Drugs Aging; 2005; 22(2):101-14. PubMed ID: 15733018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies.
    Kasper S; Brasser M; Schweizer E; Lyndon G; Prieto R
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):125-32. PubMed ID: 24290532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.
    Buoli M; Caldiroli A; Serati M
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):351-359. PubMed ID: 28075650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generalized Anxiety Disorder and Major Depressive Disorder in Pregnant and Postpartum Women: Maternal Quality of Life and Treatment Outcomes.
    Misri S; Swift E
    J Obstet Gynaecol Can; 2015 Sep; 37(9):798-803. PubMed ID: 26605449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.
    Boschen MJ
    Can J Psychiatry; 2011 Sep; 56(9):558-66. PubMed ID: 21959031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.
    Stein DJ; Baldwin DS; Baldinetti F; Mandel F
    Eur Neuropsychopharmacol; 2008 Jun; 18(6):422-30. PubMed ID: 18359203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V.
    Andrews G; Hobbs MJ; Borkovec TD; Beesdo K; Craske MG; Heimberg RG; Rapee RM; Ruscio AM; Stanley MA
    Depress Anxiety; 2010 Feb; 27(2):134-47. PubMed ID: 20058241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generalized anxiety disorder: how to treat, and for how long?
    Lam RW
    Int J Psychiatry Clin Pract; 2006; 10 Suppl 1():10-5. PubMed ID: 24931538
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line pharmacotherapy approaches for generalized anxiety disorder.
    Davidson JR
    J Clin Psychiatry; 2009; 70 Suppl 2():25-31. PubMed ID: 19371504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability.
    Montgomery S; Emir B; Haswell H; Prieto R
    Curr Med Res Opin; 2013 Oct; 29(10):1223-30. PubMed ID: 23808960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
    Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors.
    Álvarez E; Olivares JM; Carrasco JL; López-Gómez V; Rejas J
    Ann Gen Psychiatry; 2015; 14(1):2. PubMed ID: 25632294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission.
    Pollack MH
    J Clin Psychiatry; 2001; 62 Suppl 19():20-5. PubMed ID: 11577787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin.
    Both C; Kojda G; Lange-Asschenfeldt C
    Expert Rev Neurother; 2014 Jan; 14(1):29-38. PubMed ID: 24308277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validity of the Generalized Anxiety Disorder-7 scale in an acute psychiatric sample.
    Kertz S; Bigda-Peyton J; Bjorgvinsson T
    Clin Psychol Psychother; 2013; 20(5):456-64. PubMed ID: 22593009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using adjunctive treatments when first-line antidepressants fail.
    Thase ME
    J Clin Psychiatry; 2012 Jan; 73(1):e01. PubMed ID: 22316580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic strategies for the patient with treatment-resistant anxiety.
    Coplan JD; Tiffon L; Gorman JM
    J Clin Psychiatry; 1993 May; 54 Suppl():69-74. PubMed ID: 8509358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of neuroimaging studies in generalized anxiety disorder: "So where do we stand?".
    Goossen B; van der Starre J; van der Heiden C
    J Neural Transm (Vienna); 2019 Sep; 126(9):1203-1216. PubMed ID: 31222605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview and clinical presentation of generalized anxiety disorder.
    Rickels K; Rynn M
    Psychiatr Clin North Am; 2001 Mar; 24(1):1-17. PubMed ID: 11225502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.